Table 1.
Demographic data and baseline clinical characteristics of patients with ankylosing spondylitis
| Characteristic | Inflammatory lesion (+) (n = 40) | Inflammatory lesion (–) (n = 68) | p value |
|---|---|---|---|
| Age, yr | 36.9 ± 11.9 | 41.9 ± 13.5 | 0.017 |
| Male sex | 33 (82.5) | 53 (77.9) | NS |
| Disease duration, mon | 52.4 ± 54.1 | 62.9 ± 80.4 | NS |
| History of uveitis | 8 (20.0) | 14 (20.6) | NS |
| Family history of AS | 2 (5.0) | 2 (2.9) | NS |
| Positive HLA-B27 | 30 (78.9) | 55 (84.6) | NS |
| ESR, mm/hr | 39.3 ± 33.3 | 24.1 ± 21.8 | 0.014 |
| CRP, mg/dL | 3.14 ± 4.53 | 0.72 ± 1.27 | 0.002 |
| Mean ASDAS: CRP | 2.77 ± 1.33 | 1.94 ± 0.72 | 0.001 |
| Back pain | 4.38 ± 1.89 | 3.35 ± 1.49 | 0.006 |
| Duration of morning stiffness | 3.60 ± 1.88 | 2.86 ± 1.55 | 0.008 |
| Patient global assessment | 4.10 ± 1.81 | 2.88 ± 1.31 | < 0.001 |
| Peripheral pain/swelling | 3.93 ± 1.90 | 2.89 ± 1.36 | 0.002 |
| ASDAS: CRP activity state | 0.001a | ||
| Inactive (< 1.3) | 7 (17.5) | 15 (22.1) | |
| Moderate (≥ 1.3 & < 2.1) | 7 (17.5) | 29 (42.6) | |
| High (≥ 2.1 & ≤ 3.5) | 14 (35.0) | 22 (32.4) | |
| Very high (> 3.5) | 12 (30.0) | 2 (2.9) | |
| Past medical history | |||
| Sulfasalazine (n = 38) | 11 (27.5) | 27 (39.7) | NS |
| Methotrexate (n = 13) | 4 (10.0) | 9 (13.2) | NS |
| Anti-TNF agent (n = 26) | 13 (32.5) | 13 (19.1) | NS |
| NSAIDs use | |||
| Never-use (n = 14) | 8 (20.0) | 6 (8.8) | NS |
| Intermittent-use (n = 44) | 15 (37.5) | 29 (42.6) | NS |
| Continuous-use (n = 50) | 17 (42.5) | 33 (48.5) | NS |
Values are presented as mean ± SD or number (%).
NS, not significant; AS, ankylosing spondylitis; HLA, human leukocyte antigen; ESR, erythrocyte sediment rate; CRP, Creactive protein; ASDAS, Ankylosing Spondylitis Disease Activity Score; TNF, tumor necrosis factor; NSAID, nonsteroidal antiinflammatory drug.
a
Trend analysis (linear-by-linear association) by the categorization of ASDAS-CRP scores.